About
Technology
Issues
FAQ
Links
Official Page
IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.